Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
5.47
+0.02 (0.46%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Vir Biotechnology Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Vir Biotechnology stock have an average target of 33.57, with a low estimate of 14 and a high estimate of 110. The average target predicts an increase of 514.27% from the current stock price of 5.47.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Vir Biotechnology stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
Buy | 1 | 1 | 3 | 3 | 3 | 3 |
Hold | 2 | 2 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 5 | 6 | 6 | 6 | 7 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Goldman Sachs | Goldman Sachs | Strong Buy Maintains $28 → $21 | Strong Buy | Maintains | $28 → $21 | +284.26% | Apr 17, 2025 |
Barclays | Barclays | Buy Maintains $26 → $31 | Buy | Maintains | $26 → $31 | +467.25% | Feb 28, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $110 | Strong Buy | Reiterates | $110 | +1,912.81% | Feb 28, 2025 |
Needham | Needham | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +247.67% | Feb 27, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $110 | Strong Buy | Reiterates | $110 | +1,912.81% | Jan 31, 2025 |
Financial Forecast
Revenue This Year
27.30M
from 74.21M
Decreased by -63.21%
Revenue Next Year
32.13M
from 27.30M
Increased by 17.69%
EPS This Year
-3.40
from -3.83
EPS Next Year
-3.10
from -3.40
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 111.5M | 95.1M | 158.8M | ||
Avg | 27.3M | 32.1M | 60.3M | ||
Low | n/a | 4.9M | 11.8M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 50.3% | 248.4% | 394.1% | ||
Avg | -63.2% | 17.7% | 87.5% | ||
Low | - | -82.1% | -63.4% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -2.59 | -2.48 | -2.05 | ||
Avg | -3.40 | -3.10 | -2.83 | ||
Low | -3.79 | -3.96 | -4.35 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.